Related Experiment Video
Updated: Aug 5, 2026

A Next-generation Tissue Microarray (ngTMA) Protocol for Biomarker Studies
Published on: September 23, 2014
Expression of Thymidylate Synthase in Cancer: A Tissue Microarray Study Involving 17,371 Cancers from 136 Tumor
Florian Lutz1, Lisa Sophie Hannemann1, Seyma Büyücek1
1Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
Abstract:
Background/Objectives: Thymidylate synthase (TYMS) represents an important therapeutic target. Methods: In this study, TYMS expression was analyzed by immunohistochemistry on a tissue microarray containing 17,371 samples from 136 different tumor types. Results: TYMS staining was seen in 42.9% of 15,361 analyzable tumors, with weak staining in 35.4%, moderate in 5.7%, and strong in 1.8%. TYMS occurred in at least one case of 127 categories, of which 71 showed TYMS staining in at least 50% of cases, and 56 included at least one case with strong positivity. TYMS positivity occurred most commonly in lymphomas (81.3-96.5%), sarcomas and sarcomatoid carcinomas (33.3-100%), malignant melanoma (70.5-90.7%), cervical adenocarcinoma (78.3%), and squamous cell carcinomas of various sites (57.1-77.9%). High TYMS expression was linked to advanced pT (p = 0.0097), high grade (p < 0.0001), ER negativity (p < 0.0001), and PR negativity (p = 0.0002) in invasive breast cancer of no special type; high grade (p < 0.0050), high UICC stage (p = 0.0060), and nodal metastasis (p = 0.0120) in clear cell renal cell carcinoma (RCC); high grade (p < 0.05) and nodal metastasis (p = 0.0045) in papillary RCC; high Gleason grade (p < 0.0001) and advanced pT stage (p = 0.0149) in prostatic adenocarcinoma; high pT (p < 0.0001), nodal metastasis (p = 0.005), lymphatic (p = 0.0064) and venous invasion (p = 0.0005), left side location (p < 0.0001), and microsatellite instability (p < 0.0001) in colorectal adenocarcinoma; and high grade (p < 0.0001) in squamous cell carcinomas of different sites. Conclusions: TYMS is often overexpressed across different cancer entities and shows associations with several adverse histopathological parameters commonly used to describe tumor phenotypes.
Insights
Thymidylate synthase (TYMS) is frequently overexpressed in many cancer types, often correlating with aggressive tumor features. This widespread expression highlights its potential as a therapeutic target across diverse malignancies.
Area of Science:
- Oncology
- Molecular Pathology
- Cancer Therapeutics
Background:
- Thymidylate synthase (TYMS) is a critical enzyme in DNA synthesis and a recognized therapeutic target.
- Understanding TYMS expression patterns across various cancers is essential for developing targeted therapies.
Purpose of the Study:
- To comprehensively analyze the expression of TYMS across a wide spectrum of human tumors.
- To investigate the correlation between TYMS expression levels and clinicopathological parameters in different cancer types.
Main Methods:
- Immunohistochemistry was employed to assess TYMS expression.
- Analysis was performed on a large-scale tissue microarray comprising 17,371 samples from 136 distinct tumor types.
- Statistical analysis was used to correlate TYMS expression with histopathological features.
Main Results:
- TYMS staining was detected in 42.9% of 15,361 analyzable tumors, with varying intensity.
- High TYMS expression was frequently observed in lymphomas, sarcomas, malignant melanoma, cervical adenocarcinoma, and squamous cell carcinomas.
- Significant associations were found between high TYMS expression and adverse prognostic factors such as advanced tumor stage, high grade, and metastasis in multiple cancer types, including breast, renal cell carcinoma, prostate, and colorectal cancers.
Conclusions:
- TYMS is frequently overexpressed across a broad range of cancer entities.
- TYMS overexpression is often linked to aggressive histopathological features, underscoring its role in tumor progression.
- These findings support TYMS as a relevant therapeutic target in oncology, with potential implications for various cancers.
Related Concept Videos
The Tumor Microenvironment
The Tumor Microenvironment
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
